B-Multi-tissue_structure	0	9	Brainstem	Brainstem	NN	B-NP
O	10	18	auditory	auditory	NN	I-NP
O	18	19	-	-	HYPH	B-VP
O	19	25	evoked	evoke	VBN	B-NP
O	26	35	potential	potential	JJ	I-NP
O	36	46	evaluation	evaluation	NN	I-NP
O	47	49	in	in	IN	B-PP
O	50	58	children	child	NNS	B-NP
O	59	63	with	with	IN	B-PP
O	64	74	meningitis	meningitis	NN	B-NP
O	74	75	.	.	.	O

B-Multi-tissue_structure	76	85	Brainstem	Brainstem	NN	B-NP
O	86	94	auditory	auditory	NN	I-NP
O	94	95	-	-	HYPH	O
O	95	101	evoked	evoke	VBN	B-VP
O	102	111	potential	potential	NN	B-NP
O	112	113	(	(	(	O
O	113	117	BAEP	BAEP	NN	B-NP
O	117	118	)	)	)	O
O	119	122	was	be	VBD	B-VP
O	123	132	performed	perform	VBN	I-VP
O	133	135	on	on	IN	B-PP
O	136	139	101	101	CD	B-NP
O	140	148	children	child	NNS	I-NP
O	149	153	with	with	IN	B-PP
O	154	164	meningitis	meningitis	NN	B-NP
O	165	167	to	to	TO	B-VP
O	168	174	assess	assess	VB	I-VP
O	175	178	the	the	DT	B-NP
O	179	188	incidence	incidence	NN	I-NP
O	189	191	of	of	IN	B-PP
O	192	199	hearing	hear	VBG	B-VP
O	200	210	impairment	impairment	NN	B-NP
O	210	211	.	.	.	O

O	212	217	Fifty	Fifty	CD	B-NP
O	217	218	-	-	HYPH	I-NP
O	218	221	two	two	CD	I-NP
O	222	223	(	(	(	O
O	223	225	51	51	CD	B-NP
O	225	226	.	.	.	O
O	226	227	5	5	CD	B-NP
O	227	228	%	%	NN	I-NP
O	228	229	)	)	)	O
O	230	238	children	child	NNS	B-NP
O	239	242	had	have	VBD	B-VP
O	243	252	bacterial	bacterial	JJ	B-NP
O	253	263	meningitis	meningitis	NN	I-NP
O	263	264	,	,	,	O
O	265	268	six	six	CD	B-NP
O	269	270	(	(	(	O
O	270	271	5	5	CD	B-NP
O	271	272	.	.	.	O
O	272	273	9	9	CD	B-NP
O	273	274	%	%	NN	I-NP
O	274	275	)	)	)	O
O	276	279	had	have	VBD	B-VP
O	280	285	viral	viral	JJ	B-NP
O	286	296	meningitis	meningitis	NN	I-NP
O	296	297	,	,	,	O
O	298	301	and	and	CC	O
O	302	304	43	43	CD	B-NP
O	305	306	(	(	(	O
O	306	308	42	42	CD	B-NP
O	308	309	.	.	.	O
O	309	310	6	6	CD	B-NP
O	310	311	%	%	NN	I-NP
O	311	312	)	)	)	O
O	313	316	had	have	VBD	B-VP
O	317	324	aseptic	aseptic	JJ	B-NP
O	325	335	meningitis	meningitis	NN	I-NP
O	335	336	.	.	.	O

O	337	342	Fifty	Fifty	CD	B-NP
O	342	343	-	-	HYPH	I-NP
O	343	346	one	one	CD	I-NP
O	347	348	(	(	(	O
O	348	350	50	50	CD	B-NP
O	350	351	.	.	.	O
O	351	352	5	5	CD	B-NP
O	352	353	%	%	NN	I-NP
O	353	354	)	)	)	O
O	355	363	patients	patient	NNS	B-NP
O	364	368	were	be	VBD	B-VP
O	369	377	assessed	assess	VBN	I-VP
O	378	384	before	before	IN	B-PP
O	385	394	discharge	discharge	NN	B-NP
O	395	398	and	and	CC	O
O	399	401	50	50	CD	B-NP
O	402	403	(	(	(	O
O	403	405	49	49	CD	B-NP
O	405	406	.	.	.	O
O	406	407	5	5	CD	B-NP
O	407	408	%	%	NN	I-NP
O	408	409	)	)	)	O
O	410	411	9	9	CD	B-NP
O	412	416	days	day	NNS	I-NP
O	417	419	to	to	TO	B-PP
O	420	422	17	17	CD	B-NP
O	423	429	months	month	NNS	I-NP
O	430	435	later	later	RB	B-ADVP
O	436	437	(	(	(	O
O	437	441	mean	mean	NN	B-NP
O	442	443	=	=	SYM	B-VP
O	444	445	4	4	CD	B-NP
O	446	452	months	month	NNS	I-NP
O	452	453	)	)	)	O
O	453	454	.	.	.	O

O	455	459	BAEP	BAEP	NN	B-NP
O	460	470	impairment	impairment	NN	I-NP
O	471	474	was	be	VBD	B-VP
O	475	480	found	find	VBN	I-VP
O	481	483	in	in	IN	B-PP
O	484	486	28	28	CD	B-NP
O	487	488	(	(	(	O
O	488	490	27	27	CD	B-NP
O	490	491	.	.	.	O
O	491	492	7	7	CD	B-NP
O	492	493	%	%	NN	I-NP
O	493	494	)	)	)	O
O	495	497	of	of	IN	B-PP
O	498	501	101	101	CD	B-NP
O	502	510	patients	patient	NNS	I-NP
O	510	511	;	;	:	O
O	512	514	24	24	CD	B-NP
O	515	518	had	have	VBD	B-VP
O	519	532	sensorineural	sensorineural	JJ	B-ADJP
O	533	536	and	and	CC	O
O	537	541	four	four	CD	B-NP
O	542	545	had	have	VBD	B-VP
O	546	556	conductive	conductive	JJ	B-NP
O	557	561	type	type	NN	I-NP
O	562	564	of	of	IN	B-PP
O	565	572	hearing	hearing	NN	B-NP
O	573	577	loss	loss	NN	I-NP
O	577	578	,	,	,	O
O	579	582	and	and	CC	O
O	583	585	17	17	CD	B-NP
O	586	587	(	(	(	O
O	587	589	60	60	CD	B-NP
O	589	590	.	.	.	O
O	590	591	7	7	CD	B-NP
O	591	592	%	%	NN	I-NP
O	592	593	)	)	)	O
O	594	597	had	have	VBD	B-VP
O	598	608	unilateral	unilateral	JJ	B-ADJP
O	609	612	and	and	CC	O
O	613	615	11	11	CD	B-NP
O	616	617	(	(	(	O
O	617	619	39	39	CD	B-NP
O	619	620	.	.	.	O
O	620	621	3	3	CD	B-NP
O	621	622	%	%	NN	I-NP
O	622	623	)	)	)	O
O	624	627	had	have	VBD	B-VP
O	628	637	bilateral	bilateral	JJ	B-NP
O	638	648	impairment	impairment	NN	I-NP
O	648	649	.	.	.	O

O	650	657	Hearing	Hear	VBG	B-NP
O	658	667	threshold	threshold	NN	I-NP
O	668	671	was	be	VBD	B-VP
O	672	680	elevated	elevate	VBN	I-VP
O	681	683	in	in	IN	B-PP
O	684	686	22	22	CD	B-NP
O	687	688	(	(	(	O
O	688	690	21	21	CD	B-NP
O	690	691	.	.	.	O
O	691	692	8	8	CD	B-NP
O	692	693	%	%	NN	I-NP
O	693	694	)	)	)	O
O	695	703	patients	patient	NNS	B-NP
O	703	704	,	,	,	O
O	705	708	and	and	CC	O
O	709	712	the	the	DT	B-NP
O	713	718	other	other	JJ	I-NP
O	719	722	six	six	CD	I-NP
O	723	726	had	have	VBD	B-VP
O	727	736	increased	increase	VBN	I-VP
O	737	744	latency	latency	NN	B-NP
O	745	748	and	and	CC	O
O	749	758	interpeak	interpeak	JJ	B-NP
O	759	768	latencies	latency	NNS	I-NP
O	769	773	with	with	IN	B-PP
O	774	780	normal	normal	JJ	B-NP
O	781	790	threshold	threshold	NN	I-NP
O	790	791	.	.	.	O

O	792	801	Frequency	Frequency	NN	B-NP
O	802	804	of	of	IN	B-PP
O	805	809	BAEP	BAEP	NN	B-NP
O	810	820	impairment	impairment	NN	I-NP
O	821	823	or	or	CC	O
O	824	831	hearing	hearing	NN	B-NP
O	832	836	loss	loss	NN	I-NP
O	837	847	associated	associate	VBN	B-VP
O	848	852	with	with	IN	B-PP
O	853	862	bacterial	bacterial	JJ	B-NP
O	863	873	meningitis	meningitis	NN	I-NP
O	874	877	was	be	VBD	B-VP
O	878	880	34	34	CD	B-NP
O	880	881	.	.	.	O
O	881	882	6	6	CD	B-NP
O	882	883	%	%	NN	I-NP
O	884	887	and	and	CC	O
O	888	890	30	30	CD	B-NP
O	890	891	.	.	.	O
O	891	892	8	8	CD	B-NP
O	892	893	%	%	NN	I-NP
O	893	894	,	,	,	O
O	895	907	respectively	respectively	RB	B-ADVP
O	907	908	;	;	:	O
O	909	918	frequency	frequency	NN	B-NP
O	919	929	associated	associate	VBN	B-VP
O	930	934	with	with	IN	B-PP
O	935	942	aseptic	aseptic	JJ	B-NP
O	943	953	meningitis	meningitis	NN	I-NP
O	954	957	was	be	VBD	B-VP
O	958	960	20	20	CD	B-NP
O	960	961	.	.	.	O
O	961	962	9	9	CD	B-NP
O	962	963	%	%	NN	I-NP
O	964	967	and	and	CC	O
O	968	970	13	13	CD	B-NP
O	970	971	.	.	.	O
O	971	972	9	9	CD	B-NP
O	972	973	%	%	NN	I-NP
O	973	974	,	,	,	O
O	975	987	respectively	respectively	RB	B-ADVP
O	987	988	.	.	.	O

O	989	992	One	One	CD	B-NP
O	993	998	child	child	NN	I-NP
O	999	1003	with	with	IN	B-PP
O	1004	1009	viral	viral	JJ	B-NP
O	1010	1020	meningitis	meningitis	NN	I-NP
O	1021	1022	(	(	(	O
O	1022	1031	coxsackie	coxsackie	NN	B-NP
O	1032	1037	virus	virus	NN	I-NP
O	1037	1038	)	)	)	O
O	1039	1042	had	have	VBD	B-VP
O	1043	1047	mild	mild	JJ	B-NP
O	1048	1052	BAEP	BAEP	NN	I-NP
O	1053	1063	impairment	impairment	NN	I-NP
O	1063	1064	.	.	.	O

O	1065	1069	Most	Most	JJS	B-NP
O	1070	1072	of	of	IN	B-PP
O	1073	1076	the	the	DT	B-NP
O	1077	1081	BAEP	BAEP	NN	I-NP
O	1082	1092	impairment	impairment	NN	I-NP
O	1093	1095	in	in	IN	B-PP
O	1096	1099	the	the	DT	B-NP
O	1100	1109	bacterial	bacterial	JJ	I-NP
O	1110	1120	meningitis	meningitis	NN	I-NP
O	1121	1126	group	group	NN	I-NP
O	1127	1130	was	be	VBD	B-VP
O	1131	1141	associated	associate	VBN	I-VP
O	1142	1146	with	with	IN	B-PP
O	1147	1148	H	H	NN	B-NP
O	1148	1149	.	.	NN	I-NP
O	1150	1160	influenzae	influenzae	NNS	I-NP
O	1160	1161	.	.	.	O

O	1162	1173	Prospective	Prospective	JJ	B-NP
O	1174	1178	BAEP	BAEP	NN	I-NP
O	1179	1184	study	study	NN	I-NP
O	1185	1188	was	be	VBD	B-VP
O	1189	1198	performed	perform	VBN	I-VP
O	1199	1201	in	in	IN	B-PP
O	1202	1204	20	20	CD	B-NP
O	1205	1213	patients	patient	NNS	I-NP
O	1214	1222	randomly	randomly	RB	B-ADVP
O	1223	1225	at	at	IN	B-PP
O	1226	1227	0	0	CD	B-NP
O	1227	1228	.	.	.	O
O	1228	1229	3	3	CD	B-NP
O	1230	1232	to	to	TO	I-NP
O	1233	1235	18	18	CD	I-NP
O	1236	1242	months	month	NNS	I-NP
O	1243	1245	to	to	TO	B-VP
O	1246	1252	assess	assess	VB	I-VP
O	1253	1260	hearing	hear	VBG	I-VP
O	1261	1267	status	status	NN	B-NP
O	1268	1273	after	after	IN	B-PP
O	1274	1284	antibiotic	antibiotic	JJ	B-NP
O	1285	1294	treatment	treatment	NN	I-NP
O	1294	1295	,	,	,	O
O	1296	1298	10	10	CD	B-NP
O	1299	1303	with	with	IN	B-PP
O	1304	1310	normal	normal	JJ	O
O	1311	1314	and	and	CC	O
O	1315	1317	10	10	CD	B-NP
O	1318	1322	with	with	IN	B-PP
O	1323	1331	abnormal	abnormal	JJ	B-NP
O	1332	1336	BAEP	BAEP	NN	I-NP
O	1336	1337	.	.	.	O

O	1338	1341	All	All	PDT	B-NP
O	1342	1345	the	the	DT	I-NP
O	1346	1355	initially	initially	RB	I-NP
O	1356	1362	normal	normal	JJ	I-NP
O	1363	1367	BAEP	BAEP	NN	I-NP
O	1368	1376	patients	patient	NNS	I-NP
O	1377	1385	remained	remain	VBD	B-VP
O	1386	1392	normal	normal	JJ	B-ADJP
O	1392	1393	.	.	.	O

O	1394	1396	Of	Of	IN	B-PP
O	1397	1400	the	the	DT	B-NP
O	1401	1403	10	10	CD	I-NP
O	1404	1412	patients	patient	NNS	I-NP
O	1413	1417	with	with	IN	B-PP
O	1418	1426	abnormal	abnormal	JJ	B-NP
O	1427	1431	BAEP	BAEP	NN	I-NP
O	1432	1439	results	result	NNS	I-NP
O	1440	1449	initially	initially	RB	B-ADVP
O	1449	1450	,	,	,	O
O	1451	1455	four	four	CD	B-NP
O	1456	1464	returned	return	VBD	B-VP
O	1465	1467	to	to	TO	B-PP
O	1468	1474	normal	normal	JJ	B-NP
O	1474	1475	,	,	,	O
O	1476	1479	two	two	CD	B-NP
O	1480	1488	improved	improve	VBD	B-VP
O	1488	1489	,	,	,	O
O	1490	1495	three	three	CD	B-NP
O	1496	1504	remained	remain	VBD	B-VP
O	1505	1514	unchanged	unchanged	JJ	B-ADJP
O	1514	1515	,	,	,	O
O	1516	1519	and	and	CC	O
O	1520	1523	one	one	CD	B-NP
O	1524	1536	deteriorated	deteriorate	VBN	B-VP
O	1536	1537	.	.	.	O

O	1538	1541	The	The	DT	B-NP
O	1542	1551	incidence	incidence	NN	I-NP
O	1552	1554	of	of	IN	B-PP
O	1555	1562	hearing	hearing	NN	B-NP
O	1563	1567	loss	loss	NN	I-NP
O	1568	1573	after	after	IN	B-PP
O	1574	1583	bacterial	bacterial	JJ	B-NP
O	1584	1587	and	and	CC	I-NP
O	1588	1595	aseptic	aseptic	JJ	I-NP
O	1596	1606	meningitis	meningitis	NN	I-NP
O	1607	1609	is	be	VBZ	B-VP
O	1610	1614	high	high	JJ	B-ADJP
O	1614	1615	.	.	.	O

O	1616	1620	BAEP	BAEP	NN	B-NP
O	1621	1623	is	be	VBZ	B-VP
O	1624	1630	useful	useful	JJ	B-ADJP
O	1631	1633	to	to	TO	B-VP
O	1634	1640	screen	screen	VB	I-VP
O	1641	1644	for	for	IN	B-PP
O	1645	1653	possible	possible	JJ	B-NP
O	1654	1661	hearing	hearing	NN	I-NP
O	1662	1666	loss	loss	NN	I-NP
O	1667	1669	in	in	IN	B-PP
O	1670	1678	children	child	NNS	B-NP
O	1679	1683	with	with	IN	B-PP
O	1684	1694	meningitis	meningitis	NN	B-NP
O	1694	1695	,	,	,	O
O	1696	1699	and	and	CC	O
O	1700	1706	follow	follow	VB	B-VP
O	1706	1707	-	-	HYPH	O
O	1707	1709	up	up	RP	B-PRT
O	1710	1714	BAEP	BAEP	NN	B-NP
O	1715	1717	is	be	VBZ	B-VP
O	1718	1727	necessary	necessary	JJ	B-ADJP
O	1728	1731	for	for	IN	B-PP
O	1732	1737	those	those	DT	B-NP
O	1738	1746	patients	patient	NNS	I-NP
O	1747	1751	with	with	IN	B-PP
O	1752	1761	initially	initially	RB	B-NP
O	1762	1770	abnormal	abnormal	JJ	I-NP
O	1771	1775	BAEP	BAEP	NN	I-NP
O	1775	1776	.	.	.	O

